Topoisomerase I inhibitors for the treatment of brain tumors

被引：17

作者：

Feun, Lynn ^{[1
]}

Savaraj, Niramol ^{[2
]}

机构：

[1] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA

[2] Univ Miami, VA Med Ctr, Miami, FL 33125 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2008年 / 8卷 / 05期

关键词：

brain tumor; glioblastoma; topoisomerase inhibitor;

D O I：

10.1586/14737140.8.5.707

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with primary malignant brain tumors have a poor prognosis. Standard treatment includes surgical resection, radiation therapy and chemotherapy. Topoisomerase I inhibitors such as topotecan and irinotecan (CPT-11) represent one class of chemotherapy drugs that have been used in this disease. Recent clinical trials have shown major antitumor activity in recurrent glioblastoma when adding the antiangiogenesis drug bevacizumab with CPT-11. The combination of targeted agents to topoisomerase I inhibitors represent a novel and promising approach. This review will summarize clinical trials with topoisomerase I inhibitors and discuss new treatment strategies for primary malignant brain tumors.

引用

页码：707 / 716

页数：10

共 93 条

[1] Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer [J].

Allen, Jeffrey A. ;

Adlakha, Ashish ;

Bergethon, Peter R. .

ARCHIVES OF NEUROLOGY, 2006, 63 (10) :1475-1478

[2] Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor [J].

Bao, Shideng ;

Wu, Qiulian ;

Sathornsumetee, Sith ;

Hao, Yueling ;

Li, Zhizhong ;

Hjelmeland, Anita B. ;

Shi, Oing ;

McLendon, Roger E. ;

Bigner, Darell D. ;

Rich, Jeremy N. .

CANCER RESEARCH, 2006, 66 (16) :7843-7848

[3] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[4] Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11 [J].

Batchelor, TT ;

Gilbert, MR ;

Supko, JG ;

Carson, KA ;

Nabors, LB ;

Grossman, SA ;

Lesser, GJ ;

Mikkelsen, T ;

Phuphanich, S .

NEURO-ONCOLOGY, 2004, 6 (01) :21-27

[5]

Blaney SM, 1996, CANCER-AM CANCER SOC, V78, P527

[6]

BLANEY SM, 1993, CANCER RES, V53, P1032

[7] Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy:: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) [J].

Brandes, AA ;

Tosoni, A ;

Basso, U ;

Reni, M ;

Valduga, F ;

Monfardini, S ;

Amistà, P ;

Nicolardi, L ;

Sotti, G ;

Ermani, M .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) :4779-4786

[8] Irinotecan in the treatment of glioma patients - Current and future studies of the North Central Cancer Treatment Group [J].

Buckner, JC ;

Reid, JM ;

Wright, K ;

Kaufmann, SH ;

Erlichman, C ;

Ames, M ;

Cha, S ;

O'Fallon, JR ;

Schaaf, LJ ;

Miller, LL .

CANCER, 2003, 97 (09) :2352-2358

[9] Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme [J].

Chamberlain, MC .

JOURNAL OF NEURO-ONCOLOGY, 2002, 56 (02) :183-188

[10] Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma [J].

Chen, TC ;

Su, S ;

Fry, D ;

Liebes, L .

CANCER, 2003, 97 (09) :2363-2373

← 1 2 3 4 5 6 7 8 9 10 →